Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.（APLS）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · APLS · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
45
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Apellis Pharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
APLS 季度内部人买卖趋势
APLS 内幕交易卖出 · APLS 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · APLS CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
APLS 高管卖出股份 · APLS 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 14, 2026 | Dunlop A. Sinclair Director | Other | 3,544 | — | Form 4 |
| May 14, 2026 | Dunlop A. Sinclair Director | Other | 161,567 | $646K | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Award | 16,150 | — | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Award | 8,394 | — | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Award | 8,075 | — | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Award | 5,625 | — | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Other | 65,955 | $7 | Form 4 |
| May 14, 2026 | Chopas James George VP/Chief Accounting Officer | Other | 6,250 | — | Form 4 |
| May 14, 2026 | Dolsten Mikael Director | Other | 14,312 | — | Form 4 |
| May 14, 2026 | Dolsten Mikael Director | Other | 14,312 | $57K | Form 4 |
| May 14, 2026 | MELTZER LESLIE Chief Research and Development | Award | 45,220 | — | Form 4 |
| May 14, 2026 | MELTZER LESLIE Chief Research and Development | Award | 22,610 | — | Form 4 |
| May 14, 2026 | MELTZER LESLIE Chief Research and Development | Other | 45,220 | — | Form 4 |
| May 14, 2026 | MELTZER LESLIE Chief Research and Development | Other | 107,024 | $428K | Form 4 |
| May 14, 2026 | FONTEYNE PAUL R. Director | Other | 30,666 | $123K | Form 4 |
| May 14, 2026 | FONTEYNE PAUL R. Director | Other | 3,877 | — | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Award | 58,140 | — | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Award | 41,250 | — | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Award | 30,620 | — | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Award | 29,070 | — | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Other | 71,492 | $286K | Form 4 |
| May 14, 2026 | Sullivan Timothy Eugene CFO | Other | 58,140 | — | Form 4 |
| May 14, 2026 | Machiels Alec Director | Other | 150,000 | $15 | Form 4 |
| May 14, 2026 | Machiels Alec Director | Other | 3,544 | — | Form 4 |
| May 14, 2026 | Deschatelets Pascal Chief Scientific Officer | Award | 41,250 | — | Form 4 |
Chopas James George
VP/Chief Accounting Officer
日期
May 14
股数
65,955
均价
$0.00
总金额
$7
MELTZER LESLIE
Chief Research and Development
日期
May 14
股数
107,024
均价
$4.00
总金额
$428K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 APLS 内幕交易
APLS 内幕交易
Apellis Pharmaceuticals, Inc.（APLS）内幕交易数据来源于公司内部人（包括Chopas James George (VP/Chief Accounting Officer), Sullivan Timothy Eugene (CFO), Deschatelets Pascal (Chief Scientific Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。APLS内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Apellis Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
APLS 内幕交易 · 5个问题Apellis Pharmaceuticals, Inc.（APLS）的内部人包括高管和董事，如Chopas James George (VP/Chief Accounting Officer), Sullivan Timothy Eugene (CFO), Deschatelets Pascal (Chief Scientific Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026